# Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

> **NCT06815991** · PHASE1 · RECRUITING · sponsor: **Metro International Biotech, LLC** · enrollment: 32 (estimated)

## Conditions studied

- Healthy Adults

## Interventions

- **DRUG:** MIB-725

## Key facts

- **NCT ID:** NCT06815991
- **Lead sponsor:** Metro International Biotech, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-11
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06815991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06815991, "Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06815991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*